Literature DB >> 3128096

Impaired fibrinolysis in coronary artery disease.

R B Francis1, D Kawanishi, T Baruch, P Mahrer, S Rahimtoola, D I Feinstein.   

Abstract

We assessed endogenous endothelial-dependent fibrinolysis in 99 subjects with coronary artery disease (CAD) documented by angiography and in 28 control subjects with normal coronary arteries on angiography. We used specific, sensitive assays for plasma tissue-type plasminogen activator (t-PA) antigen, t-PA activity, plasminogen activator inhibitor (PAI) activity, plasminogen, and alpha-2 plasmin inhibitor (alpha-2 PI). Mean PAI activity was significantly higher, and mean t-PA activity after venous occlusion of the upper arm (a standard test of the capacity of vascular endothelium to release t-PA) was significantly lower in subjects with CAD than in subjects with normal coronary arteries. The mean increment in t-PA antigen after venous occlusion was significantly lower than normal in subjects with CAD with onset of symptoms before age 45 years. Subjects with CAD had a significantly increased mean plasma fibrinogen level compared with control subjects, and a significant positive correlation was observed between PAI activity and plasma fibrinogen in subjects with CAD. No significant abnormalities of plasminogen or alpha-2 PI were observed in any subset of subjects with CAD. These data support an association between impaired fibrinolysis and CAD, with contributions from both increased PAI activity and in younger subjects from reduced endothelial t-PA release.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3128096     DOI: 10.1016/0002-8703(88)90878-2

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  15 in total

1.  Hyperbaric oxygen therapy prevents coagulation disorders in an experimental model of multiple organ failure syndrome.

Authors:  Francesco Imperatore; Salvatore Cuzzocrea; Domenico De Lucia; Marcella Sessa; Barbara Rinaldi; Annalisa Capuano; Giovanni Liguori; Amelia Filippelli; Francesco Rossi
Journal:  Intensive Care Med       Date:  2006-09-15       Impact factor: 17.440

2.  Effects of doxazosin and atenolol on the fibrinolytic system in patients with hypertension and elevated serum cholesterol.

Authors:  J H Jansson; B Johansson; K Boman; T K Nilsson
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

3.  Plasma fibrinogen as cardiovascular risk factor.

Authors:  L Breimer
Journal:  Diabetologia       Date:  1995-05       Impact factor: 10.122

Review 4.  Genetic modifiers of atherosclerosis in mice.

Authors:  J W Knowles; N Maeda
Journal:  Arterioscler Thromb Vasc Biol       Date:  2000-11       Impact factor: 8.311

5.  Who Should Receive Hormone Replacement Therapy?

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1996       Impact factor: 2.300

6.  Relationship between plasma plasminogen activator inhibitor-1 activity and VLDL triglyceride concentration, insulin levels and insulin sensitivity: studies in randomly selected normo- and hypertriglyceridaemic men.

Authors:  A Asplund-Carlson; A Hamsten; B Wiman; L A Carlson
Journal:  Diabetologia       Date:  1993-09       Impact factor: 10.122

Review 7.  Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis.

Authors:  I Juhan-Vague; M C Alessi; P Vague
Journal:  Diabetologia       Date:  1991-07       Impact factor: 10.122

Review 8.  Clinical disorders of fibrinolysis: a critical review.

Authors:  R B Francis
Journal:  Blut       Date:  1989-07

9.  Analysis of plasma fibrinolysis in the patients with acute cerebral infarction.

Authors:  Y D Shang; X M Liu; Z Cai; M S Yang
Journal:  J Tongji Med Univ       Date:  1995

10.  High PAI activity with correlation to triglyceride and HDL cholesterol values in patients with coronary artery disease with no difference in survivors of myocardial infarction.

Authors:  K Ihnken; W Speiser; W Ruf; W Thiel; M Schlepper; G Müller-Berghaus
Journal:  Ann Hematol       Date:  1993-11       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.